Title:
MULTI-TARGET KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/186812
Kind Code:
A1
Abstract:
The present application relates to the technical field of biomedicine, and specifically discloses a multi-target kinase inhibitor and a pharmaceutical composition comprising the multi-target kinase inhibitor, and further discloses a preparation method and a use of the multi-target kinase inhibitor. The multi-target kinase inhibitor provided by the present application has a general structural formula as shown by formula (I), wherein the structure of R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit enzymatic activity of RET, VEGFR3 and PDGFRA, and can effectively treat diseases regulated by a multi-target kinase and associated with an abnormality of a signal transduction pathway of the multi-target kinase, including cancers in the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eyes, liver, skin, head and/or neck and distal metastatic carcinomas thereof, as well as lymphoma, sarcoma, and leukemia, etc. The pharmaceutical composition of the present application comprises the multi-target kinase inhibitor as an active component, which accounts for 1% to 50% by weight of the composition.
Inventors:
LIU BING (CN)
DAI JINGSI (CN)
WANG YAN (CN)
QIAN XUEQI (CN)
DONG JUNJUN (CN)
LIU XIHONG (CN)
DENG LIANWU (CN)
XIE SHUANG (CN)
LI DAPING (CN)
CHEN NENGAN (CN)
MA JIN (CN)
DAI JINGSI (CN)
WANG YAN (CN)
QIAN XUEQI (CN)
DONG JUNJUN (CN)
LIU XIHONG (CN)
DENG LIANWU (CN)
XIE SHUANG (CN)
LI DAPING (CN)
CHEN NENGAN (CN)
MA JIN (CN)
Application Number:
PCT/CN2019/121231
Publication Date:
September 24, 2020
Filing Date:
November 27, 2019
Export Citation:
Assignee:
GUANGZHOU LIUSHUN BIO TEC CO LTD (CN)
BEIKE HUAXIA BIOMEDICAL TECH CO LTD (CN)
BEIKE HUAXIA BIOMEDICAL TECH CO LTD (CN)
International Classes:
C07D239/88; A61K31/517; A61P35/00; A61P35/02
Domestic Patent References:
| WO2018145621A1 | 2018-08-16 |
Foreign References:
| EP0860433A1 | 1998-08-26 | |||
| EP1243582A1 | 2002-09-25 | |||
| CN109776432A | 2019-05-21 |
Other References:
RAVEZ, S. ET AL.: "Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 23, no. 22, 24 October 2015 (2015-10-24), XP055734286, ISSN: 0968-0896, DOI: 20200131124758A
"Chinese Pharmacopoeia", vol. IV, 2015
See also references of EP 3929182A4
"Chinese Pharmacopoeia", vol. IV, 2015
See also references of EP 3929182A4
Attorney, Agent or Firm:
SCIHEAD IP LAW FIRM (CN)
Download PDF: